$NRBO +750% Potential Upside - ReversalNASDAQ:NRBO +750% Potential Upside - Reversal. It is squeezing almost a year. It is about time for reversal. With volume, it would run multi days. by MarketToday441
NRBO | Huge Gains Incoming | OversoldNeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.Longby DivergenceSeeker12128
NRBO Spike Catcher 101Here is NRBO since the violation of its major resistance is at a point of a massive breakout to the following targets. The recent volume within the load-zone is also indicating a bullish breakout to arrive. Longby Zivul33Updated 11
NRBO 400% Upside Potential | Covid-19 TreatmentOn 4/20/2021 HC Wainwright brokerage Reiterated Rating to Buy and a Price Target of $16.00 for NRBO But how come? What`s the catalyst? Why NeuroBo Pharmaceuticals was up 40% yesterday? Richard J. Kang, CEO: "Throughout the first quarter of 2021, we continued to make progress advancing the 60-patient Phase 2/3 clinical trial of our lead drug candidate, ANA001, a proprietary oral niclosamide formulation, as a treatment for moderate to severe COVID-19." "we expect to report preclinical in vitro data demonstrating Gemcabene's ability to treat COVID-19 variants alone and in combination with ANA001." "NeuroBo has the financial foundation to fund operations at the current level into the fourth quarter of 2021 and we expect to achieve a number of value-creating milestones with our COVID-19 programs in the coming months." Besides the Covid-19 treatment, NeuroBo Pharmaceuticals has a current portfolio of four drug candidates focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. The Market Cap if only 88.473Mil at the time or writing! Longby TopgOptions448
$NRBO is gonna fall todayPupm&Dump trading strategy idea. $NRBO is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $3,69; stop-loss — $4,12; take-profit — $2,83. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!Shortby KozakHlibUpdated 223
NRBO Technical Analysis 🧙NeuroBo Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing therapies for patients with diabetic neuropathy and Alzheimer's disease. Its product candidate comprises NB-01, which is primarily focused on the development of a treatment for painful diabetic neuropathy; NB-02, which treat the symptoms of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid-beta plaque deposition; Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. If you understand the idea,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!Longby unfair_advantage2
Interesting Bottom PlayLooks to have found a bottom around 4.8-5.2. Huge volume spike a few days ago, someone big probably built a position ahead of news. We'll see where this goes. Longby westonnn220